Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial - 17/03/19

Ariel A. Cohen ^{a, ⁎} , Hein Heidbuchel ^b, Jean-Yves Le Heuzey ^c, Raffaele De Caterina ^d, Jose L. Merino ^e, James Jin ^f, Michael Melino ^f, Shannon M. Winters ^g, Andreas Goette ^h, Gregory Y.H. Lip ⁱ

^a Hôpital Saint Antoine, Hôpital Tenon, Université Pierre et Marie Curie (Paris VI), Paris, France 

^b Antwerp University and University Hospital, Cardiology, Antwerp, Belgium 

^c Georges Pompidou Hospital, René Descartes University, Cardiology and Arrhythmology, Paris, France 

^d G. d'Annunzio University, Institute of Cardiology, Chieti, Italy 

^e Hospital Universitario La Paz, Universidad Europea, Madrid, Spain 

^f Daiichi Sankyo Pharma Development, Edison, USA 

^g Daiichi Sankyo, Inc., Parsippany, USA 

^h St. Vincenz Hospital, Paderborn, Germany 

ⁱ Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK 

^⁎Reprint requests: Professor Ariel A. Cohen, Service de Cardiologie, AP-HP – Hôpital Saint-Antoine, 184, rue du faubourg saint Antoine, Paris Cedex 12, and UPMC Université Paris Sorbonne, Paris, France.Service de Cardiologie, AP-HP – Hôpital Saint-Antoine, 184, rue du faubourg saint Antoine, Paris Cedex 12, and UPMC Université Paris SorbonneParisFrance

Le texte complet de cet article est disponible en PDF.